Search

Luca Gattinoni

from Washington, DC
Age ~52
Get Report
Also known as:
Gattinoni Luca
Phone and address:
1461 Florida Ave NW, Washington, DC 20009
(202) 483-6286
Connected to:
Briana L Gattis, 36Bruce W Gattis, 86Christopher Gattis, 36Claudia F Gattis, 79Katie L Gattis, 41Mallori J Gattis, 38Margaret F Gattis, 88Paula Gattis, 80Suzanne K Gattis, 62Frederic A Gattison, 51

Luca Gattinoni Phones & Addresses

  • 1461 Florida Ave NW, Washington, DC 20009 (202) 483-6286
  • 1815 18Th St, Washington, DC 20009 (202) 483-6286
  • 1317 Corcoran St, Washington, DC 20009 (202) 483-6286

Resumes

Resumes

Luca Gattinoni Photo 1

Professor, Chair For Functional Immune Cell Modulation

View page
Location:
9000 Rockville Pike, Bethesda, MD 20892
Industry:
Research
Work:
Regensburg Center For Interventional Immunology
Professor, Chair For Functional Immune Cell Modulation
National Cancer Institute (Nci) Jul 2008 - Mar 2013
Staff Scientist
National Cancer Institute (Nci) Jul 2008 - Mar 2013
Principal Investigator
National Cancer Institute (Nci) Nov 2006 - Jul 2008
Research Fellow
National Cancer Institute (Nci) Apr 2003 - Nov 2006
Visiting Fellow
Education:
Università Degli Studi Di Milano 1998 - 2003
Università Degli Studi Di Milano 1992 - 1998
Doctor of Medicine, Doctorates, Medicine
Skills:
Cancer Research
Flow Cytometry
Cell Biology
Immunology
Cancer
Translational Research
Animal Models
Cell Therapy
Languages:
English
Italian
French
Luca Gattinoni Photo 2

Luca Gattinoni

View page

Publications

Us Patents

T-Cells Modified To Overexpress Phf19

View page
US Patent:
20200289562, Sep 17, 2020
Filed:
Jun 5, 2018
Appl. No.:
16/619570
Inventors:
- Bethesda MD, US
Luca Gattinoni - Washington DC, US
Assignee:
The United States of America,as represented by the Secretary,Department of Health and Human Services - Bethesda MD
International Classification:
A61K 35/17
C12N 15/63
C07K 14/435
A61P 35/00
Abstract:
Provided is a mammalian T cell modified to express the Phf19 at a level that is higher than the level of Phf19 expressed by a T cell that has not been modified to express Phf19. Provided is a genetically-modified mammalian T cell comprising a genetic expression vector comprising (a) virally-, bacterially-, or both virally- and bacterially-derived genetic sequences and (b) a genetic sequence encoding Phf19, whereby the genetic sequence encoding Phf19 within the vector is expressed within the T cell. Pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells by epigenetic reprogramming are also provided.

T Cells Modified To Overexpress C-Myb

View page
US Patent:
20180258394, Sep 13, 2018
Filed:
Aug 24, 2016
Appl. No.:
15/754078
Inventors:
- Bethesda MD, US
Yun Ji - Germantown MD, US
Luca Gattinoni - Washington DC, US
Assignee:
The USA, as represented by the Secretary Department of Health and Human Services - Bethesda MD
International Classification:
C12N 5/0783
C07K 14/82
C07K 14/725
A61K 35/17
Abstract:
Provided is an isolated or purified T cell comprising an antigen-specific receptor, wherein the antigen-specific receptor is a T cell receptor (TCR) or a chimeric antigen receptor (CAR), wherein the T cell has been modified to express a transcription factor at a level that is higher than the level of the transcription factor expressed by a T cell that has not been modified to express the transcription factor, wherein the transcription factor is V-Myb Avian Myeloblastosis Viral Oncogene Homolog (c-Myb), a functional variant of c-Myb, or a functional fragment of c-Myb. Related populations of cells, pharmaceutical compositions, methods of treating a disease, and methods of inhibiting the differentiation of T cells are also provided.

Methods Of Producing T Memory Stem Cell Populations

View page
US Patent:
20150299656, Oct 22, 2015
Filed:
Sep 6, 2012
Appl. No.:
14/425713
Inventors:
Luca Gattinoni - Washington DC, US
Enrico Lugli - Bethesda MD, US
Mario Roederer - Washington DC, US
Nicholas P. Restifo - Chevy Chase MD, US
Assignee:
The United States of America, as represented by th Secretary, Department of Health and Human Service - Bethesda MD
International Classification:
C12N 5/0783
A61K 35/17
Abstract:
Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating naïve T cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve T cells and expanding the numbers of naïve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO−, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.

Compositions And Methods For Enhancing Cancer Immunotherapy

View page
US Patent:
20150275209, Oct 1, 2015
Filed:
Oct 17, 2013
Appl. No.:
14/436947
Inventors:
- Bethesda MD, US
Nicholas P. Restifo - Chevy Chase MD, US
Luca Gattinoni - Washington DC, US
Assignee:
The United States of America, as represented by the Secretary, Dept. of Health and Human Service - Bethesda MD
International Classification:
C12N 15/113
A61K 39/00
A61K 35/17
Abstract:
The invention provides an isolated or purified CD8+? T cell which comprises an antigen-specific T cell receptor and an exogenous nucleic acid encoding a microRNA-155 (miR-155) molecule, and methods of preparing the same. The invention also provides a pharmaceutical composition comprising the CD8+ T cell a carrier. Further provided is a method for treating or preventing a medical condition, such as cancer, by adoptively transferring to a mammal an amount of the CD8+? T cells effective to treat or prevent the medical condition.
Control profile
Luca Gattinoni from Washington, DC, age ~52 Get Report